Cargando…

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crespo-Facorro, Benedicto, Ruiz-Veguilla, Miguel, Vázquez-Bourgon, Javier, Sánchez-Hidalgo, Ana C., Garrido-Torres, Nathalia, Cisneros, Jose M., Prieto, Carlos, Sainz, Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982825/ https://www.ncbi.nlm.nih.gov/pubmed/33762960 http://dx.doi.org/10.3389/fphar.2021.646701

Ejemplares similares

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2022)

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
por: Garrido-Sánchez, Lucía, et al.
Publicado: (2022)

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
por: Gómez-Revuelta, Marcos, et al.
Publicado: (2018)

Schizophrenia Gene Expression Profile Reverted to Normal Levels by Antipsychotics
por: Crespo-Facorro, Benedicto, et al.
Publicado: (2015)

Altered gene expression in antipsychotic-induced weight gain
por: Crespo-Facorro, Benedicto, et al.
Publicado: (2019)

Sex differences in gene expression related to antipsychotic induced weight gain
por: Sainz, Jesus, et al.
Publicado: (2019)

The impact of COVID-19 pandemic on the psychological well-being among health care workers: A 6-month cohort longitudinal survey study
por: Canal-Rivero, Manuel, et al.
Publicado: (2023)

Reelin Alterations, Behavioral Phenotypes, and Brain Anomalies in Schizophrenia: A Systematic Review of Insights From Rodent Models
por: Sánchez-Hidalgo, Ana C., et al.
Publicado: (2022)

Epidemiology of infection, transmission and COVID-19 outcomes among mental health users and workers in a comprehensive network of long-term mental health facilities: Retrospective observational population-base study
por: Canal-Rivero, Manuel, et al.
Publicado: (2023)

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
por: Gómez-Revuelta, Marcos, et al.
Publicado: (2020)

Longitudinal trajectories in negative symptoms and changes in brain cortical thickness: 10-year follow-up study
por: Canal-Rivero, Manuel, et al.
Publicado: (2023)

COVID-19 Infection During Pregnancy and Risk of Neurodevelopmental Disorders in Offspring: Time for Collaborative Research
por: López-Díaz, Álvaro, et al.
Publicado: (2021)

Blood Gene Expression Profile Predicts Response to Antipsychotics
por: Sainz, Jesus, et al.
Publicado: (2018)

Trauma and stressor-related disorders among health care workers during COVID-19 pandemic and the role of the gender: A prospective longitudinal survey.
por: Canal-Rivero, Manuel, et al.
Publicado: (2022)

Short-term emotional impact of COVID-19 pandemic on Spaniard health workers
por: Rodriguez-Menéndez, Gonzalo, et al.
Publicado: (2021)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
por: Sanchez-Gistau, Vanessa, et al.
Publicado: (2023)

Cervical cancer screening and psychosis: a longitudinal retrospective study comparing women with schizophrenia spectrum disorders and the general population
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2022)

S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT
por: López-Díaz, Álvaro, et al.
Publicado: (2020)

M97. PREDICTORS OF TRANSITION TO SCHIZOPHRENIA IN BRIEF PSYCHOTIC DISORDER: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT
por: López-Díaz, Álvaro, et al.
Publicado: (2020)

COVID-19 una oportunidad única para explorar la relación entre la infección prenatal materna, el desarrollo cerebral y los trastornos neuropsiquiátricos en la descendencia
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2021)

COVID-19 una oportunidad única para explorar la relación entre la infección prenatal materna, el desarrollo cerebral y los trastornos neuropsiquiátricos en la descendencia
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2021)

Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis
por: Muntané, Gerard, et al.
Publicado: (2023)

T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS
por: Tordesillas-Gutiérrez, Diana, et al.
Publicado: (2018)

F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS: RESULTS FROM A 3-YEAR LONGITUDINAL STUDY
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2018)

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2014)

Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population
por: Canal-Rivero, M., et al.
Publicado: (2021)

The role of antipsychotics against COVID-19: A topic for debate
por: Canal-Rivero, M., et al.
Publicado: (2021)

Brief greeting and shared vision()
por: Crespo-Facorro, Benedicto
Publicado: (2020)

Mental health and the SARS-CoV-2 pandemic
por: Crespo-Facorro, Benedicto
Publicado: (2020)

Mental health and the SARS-CoV-2 pandemic
por: Crespo-Facorro, Benedicto
Publicado: (2020)

Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series
por: Valdés-Florido, María José, et al.
Publicado: (2020)

Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series
por: Valdés-Florido, María José, et al.
Publicado: (2020)

Aripiprazole-induced liver injury: a spontaneous reporting database study
por: Gao, Yunjuan, et al.
Publicado: (2023)

Neuroanatomical Differences between First-Episode Psychosis Patients with and without Neurocognitive Deficit: A 3-Year Longitudinal Study
por: Ayesa-Arriola, Rosa, et al.
Publicado: (2013)

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin
por: Aguilar, Lourdes, et al.
Publicado: (2019)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program
por: Pardo-de-Santayana, Guillermo, et al.
Publicado: (2020)

Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2020)

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis
por: Vázquez-Bourgon, Javier, et al.
Publicado: (2019)

The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
por: Perry, Benjamin I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q5e5l6b05ljshjnambenrji0ln